3 transcripts
Earnings call transcript
2024 Q2
1 Aug 24
to opportunities where we can continue presenting promising data that support deep and durable responses, further highlighting zanidatamab's potential to provide
Earnings call transcript
2024 Q1
2 May 24
for research support and other payments.
The decrease in revenue from Jazz was a result of transfer responsibility for certain clinical trials regarding
Earnings call transcript
2023 Q4
6 Mar 24
as illustrated in preclinical studies. The strategic design aims to enhance response rates across diverse expression profiles without compromising safety due
- Prev
- 1
- Next